Marc Auriacombe
Overview
Explore the profile of Marc Auriacombe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
2210
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chirokoff V, Tessier A, Serre F, Dupuy M, Auriacombe M, Chanraud S, et al.
Br J Clin Psychol
. 2025 Feb;
PMID: 39960195
Background: Medication non-adherence is a leading cause of treatment failure in psychiatric populations. However, current studies highlight the lack of methodological guidance on medication assessments. Ecological Momentary Assessment (EMA), using...
2.
Chapron S, Bonazzi G, Di Lodovico L, de Ternay J, Landmann C, Nourredine M, et al.
J Psychopharmacol
. 2025 Feb;
:2698811241308613.
PMID: 39891564
Background: In the context of the need to increase treatment options for substance use disorders, recent research has evaluated the therapeutic potential of psychedelics. However, there is an incomplete understanding...
3.
Sanchez Ortuno M, Pecune F, Coelho J, Micoulaud-Franchi J, Salles N, Auriacombe M, et al.
JMIR Ment Health
. 2025 Jan;
12():e51022.
PMID: 39815642
Background: Fully automated digital interventions delivered via smartphone apps have proven efficacious for a wide variety of mental health outcomes. An important aspect is that they are accessible at a...
4.
Baillet E, Auriacombe M, Romao C, Garnier H, Gauld C, Vacher C, et al.
Transl Psychiatry
. 2024 Dec;
14(1):497.
PMID: 39695105
Addiction is considered a chronic disorder that requires long-term treatment. Early identification of predictors of outcome may enable better and early adjustment of treatment. Daily fluctuations of craving have been...
5.
Lalanne L, Davalos J, Audran M, Hamelin N, Chauvin C, Briand-Madrid L, et al.
Subst Use Misuse
. 2024 Dec;
60(3):393-402.
PMID: 39654096
Background: Opioid Use Disorder (OUD) often provokes dramatic consequences in terms of increased morbi-mortality. Two medications have mainly been worldwide used for OUD (MOUD), buprenorphine and methadone. Recently, however, some...
6.
Perrin S, Fillol A, Moriceau S, Le Tirant L, Allache A, Serre F, et al.
Harm Reduct J
. 2024 Nov;
21(1):207.
PMID: 39580463
Context: Regular alcohol use is a predominant risk factor for disease, injury, and social harm. While robust evidence is advocating for implementing interventions to reduce the harms of illegal substance...
7.
Kervran C, Francis-Oliviero F, Kret M, Burtin A, Ratel R, Clet E, et al.
BMJ Open
. 2024 Nov;
14(11):e087541.
PMID: 39532364
Introduction: In 2021, among French women who smoked when they knew they were pregnant, 59% still smoked at the end of pregnancy. Support for pregnant women to stop smoking must...
8.
Roux P, Faye A, Sagaon-Teyssier L, Donadille C, Briand Madrid L, Carrieri M, et al.
Drug Alcohol Rev
. 2024 Oct;
44(1):275-287.
PMID: 39353607
Introduction: The co-use of stimulants and opioids, including opioid agonist treatment (OAT), is very prevalent worldwide. A large body of data exists on the association between stimulant use and its...
9.
Baillet E, Serre F, Auriacombe M
Arch Public Health
. 2024 Sep;
82(1):167.
PMID: 39334481
Worldwide, health professionals from all specialties are encouraging patients to reduce alcohol use if not abstain, and abstinence is clearly encouraged for tobacco. However, for users of substances that meet...
10.
Serre F, Gauld C, Lambert L, Baillet E, Beltran V, Daulouede J, et al.
Addiction
. 2024 Aug;
120(1):48-58.
PMID: 39210697
Background And Aims: Ecological momentary assessment (EMA) studies have previously demonstrated a prospective influence of craving on substance use in the following hours. Conceptualizing substance use as a dynamic system...